Axsome Therapeutics (AXSM) Short term Debt (2022 - 2025)
Historic Short term Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $70.0 million.
- Axsome Therapeutics' Short term Debt rose 76090.27% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 76090.27%. This contributed to the annual value of $8.3 million for FY2024, which is 2931.17% up from last year.
- Per Axsome Therapeutics' latest filing, its Short term Debt stood at $70.0 million for Q3 2025, which was up 76090.27% from $70.0 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Short term Debt ranged from a high of $70.0 million in Q2 2025 and a low of $5.9 million during Q4 2022
- In the last 4 years, Axsome Therapeutics' Short term Debt had a median value of $6.8 million in 2022 and averaged $15.9 million.
- Per our database at Business Quant, Axsome Therapeutics' Short term Debt plummeted by 468.57% in 2023 and then skyrocketed by 89431.82% in 2025.
- Axsome Therapeutics' Short term Debt (Quarter) stood at $5.9 million in 2022, then grew by 8.59% to $6.4 million in 2023, then grew by 29.31% to $8.3 million in 2024, then soared by 744.9% to $70.0 million in 2025.
- Its Short term Debt was $70.0 million in Q3 2025, compared to $70.0 million in Q2 2025 and $8.6 million in Q1 2025.